Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research

Model-based drug discovery: implementation and impact

(2013) Sandra A.G. Visser et al.   DRUG DISCOVERY TODAY

The virtue of translational PKPD modeling in drug discovery: selecting the right clinical candidate while sparing animal lives

(2013) Tjerk Bueters et al.   DRUG DISCOVERY TODAY

Pharmacokinetics and the drug–target residence time concept

(2013) Göran Dahl et al.   DRUG DISCOVERY TODAY

Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials

(2013) Thomas H. Marsilje et al.   JOURNAL OF MEDICINAL CHEMISTRY

Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic-Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor

(2012) H. Wong et al.   CLINICAL CANCER RESEARCH

Mathematical modeling of tumor growth and tumor growth inhibition in oncology drug development

(2012) Apexa Bernard et al.   Expert Opinion on Drug Metabolism & Toxicology

Pharmacokinetic-Pharmacodynamic Analysis of Vismodegib in Preclinical Models of Mutational and Ligand-Dependent Hedgehog Pathway Activation

(2011) H. Wong et al.   CLINICAL CANCER RESEARCH

BRAFV600E: Implications for Carcinogenesis and Molecular Therapy

(2011) E. R. Cantwell-Dorris et al.   MOLECULAR CANCER THERAPEUTICS

Systems Pharmacology: Bridging Systems Biology and Pharmacokinetics-Pharmacodynamics (PKPD) in Drug Discovery and Development

(2011) Piet H. van der Graaf et al.   PHARMACEUTICAL RESEARCH

Imaging of Plasmodium Liver Stages to Drive Next-Generation Antimalarial Drug Discovery

(2011) S. Meister et al.   SCIENCE

Application of In Vivo Animal Models to Characterize the Pharmacokinetic and Pharmacodynamic Properties of Drug Candidates in Discovery Settings

(2010) Benny Amore et al.   COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING

Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Inhibition and Biomarker Modulation by the Novel Phosphatidylinositol 3-Kinase Inhibitor GDC-0941

(2010) L. Salphati et al.   DRUG METABOLISM AND DISPOSITION

Assessing brain free fraction in early drug discovery

(2010) Kevin D Read et al.   Expert Opinion on Drug Metabolism & Toxicology

Practical evaluation of a mouse with chimeric human liver model for hepatitis C virus infection using an NS3-4A protease inhibitor

(2010) N. Kamiya et al.   JOURNAL OF GENERAL VIROLOGY

Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice

(2010) Nelson L. Jumbe et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies

(2010) Vishal S Vaidya et al.   NATURE BIOTECHNOLOGY

The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery

(2010) Dennis A. Smith et al.   NATURE REVIEWS DRUG DISCOVERY

Optimising in vivo pharmacology studies—Practical PKPD considerations

(2010) Johan Gabrielsson et al.   JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS

Practical Anticipation of Human Efficacious Doses and Pharmacokinetics Using In Vitro and Preclinical In Vivo Data

(2009) Tycho Heimbach et al.   AAPS Journal

Predicting Oral Clearance in Humans

(2009) Vikash K Sinha et al.   CLINICAL PHARMACOKINETICS

Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations

(2009) Johan Gabrielsson et al.   DRUG DISCOVERY TODAY

Incorporating Receptor Theory in Mechanism-Based Pharmacokinetic-Pharmacodynamic (PK-PD) Modeling

(2009) Bart A. Ploeger et al.   Drug Metabolism and Pharmacokinetics

Scaling Pharmacodynamics from In Vitro and Preclinical Animal Studies to Humans

(2009) Donald E. Mager et al.   Drug Metabolism and Pharmacokinetics

Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic–pharmacodynamic modeling of biologics

(2009) Leonid Gibiansky et al.   Expert Opinion on Drug Metabolism & Toxicology

Population Pharmacokinetic Model of the Pregabalin-Sildenafil Interaction in Rats: Application of Simulation to Preclinical PK-PD Study Design

(2009) Gregor Bender et al.   PHARMACEUTICAL RESEARCH

Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100

(2008) Rosie Z. Yu et al.   BIOCHEMICAL PHARMACOLOGY

Development of Translational Pharmacokinetic–Pharmacodynamic Models

(2008) DE Mager et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Monoclonal Antibody Pharmacokinetics and Pharmacodynamics

(2008) W Wang et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Plasma / Serum Protein Binding Determinations

(2008) Michael Banker et al.   CURRENT DRUG METABOLISM

PK/PD modelling and simulations: utility in drug development

(2008) Iris Rajman   DRUG DISCOVERY TODAY

Pharmacokinetic-Pharmacodynamic Modeling of Biomarker Response and Tumor Growth Inhibition to an Orally Available cMet Kinase Inhibitor in Human Tumor Xenograft Mouse Models

(2008) S. Yamazaki et al.   DRUG METABOLISM AND DISPOSITION

Validation of a Rapid Equilibrium Dialysis Approach for the Measurement of Plasma Protein Binding

(2008) Nigel J. Waters et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models

(2008) S. Wang et al.   MOLECULAR CANCER THERAPEUTICS

Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research

(2008) M DANHOF et al.   TRENDS IN PHARMACOLOGICAL SCIENCES